Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta-Analysis and Clinical Decision Framework.

Cancer Med · 2025 · PMC12701129 · PMID 41388641

Europe PMC DOI

hedged sentences

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendp = 0.075so close (0.05 < p ≤ 0.1)

Baseline cirrhosis showed a trend toward reduced efficacy (β = 0.41, SE = 0.23, p = 0.075).

also in 53,322 other papers

a nonsignificant trendno p-value reported

Head‐to‐head comparisons showed GLP‐1RAs superior to insulin (HR 0.29, 95% CI: 0.13–0.67), sulfonylureas (HR 0.54, 95% CI: 0.31–0.94), and a nonsignificant trend toward superiority over SGLT‐2 inhibitors (HR 0.87, 95% CI: 0.52–1.45). 3.4.

also in 5,406 other papers

did not reach statistical significanceno p-value reported

While the association did not reach statistical significance in patients with cirrhosis (HR 0.65, 95% CI: 0.39–1.10), modeled absolute risk reductions remain clinically meaningful.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.